Glenmark Pharmaceuticals Ltd has partnered with Pfizer to launch Abrocitinib in India, a first-of-its-kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD). The partnership aims to ensure the availability of this effective treatment for Indian patients suffering from moderate-to-severe AD with improved efficacy and oral convenience to patients. Abrocitinib provides rapid itch relief, sustained disease control, and improved quality of life for patients.
Abrocitinib, developed by Pfizer, has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies. The treatment will be co-marketed under the brand names JABRYUS® and CIBINQO® by Glenmark and Pfizer respectively.
Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd. said, “This partnership will help us ensure the availability of this effective treatment for the Indian patients suffering from moderate-to-severe AD; and further strengthen our position in the dermatology therapy space.”
